Results 181 to 190 of about 92,046 (305)

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, Volume 20, Issue 3, Page 779-803, March 2026.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Urothelial cancer

, 2018
openaire   +3 more sources

First-line enfortumab vedotin-pembrolizumab versus nivolumab plus gemcitabine-cisplatin in metastatic urothelial cancer: a cost-effectiveness study. [PDF]

Front Public Health
Ying H, Fu B.
europepmc   +1 more source

Expression of Nectin‐4 and Trop‐2 in upper tract urothelial carcinoma: implications for biomarker‐driven antibody‐drug conjugate therapy

The Journal of Pathology: Clinical Research, Volume 12, Issue 2, March 2026.
Abstract Recent advancements in antibody‐drug conjugates, including FDA‐approved therapies targeting Nectin‐4 and Trop‐2, have transformed the cancer treatment landscape, including upper tract urothelial carcinoma (UTUC). However, varied treatment effects and drug‐associated adverse effects raise the question of whether patients should be selected ...
Ping Shi, Qingqing Wu, Yong Zhang, Tiane Chen, Joshua I. Warrick, David J. DeGraff, Jay D. Raman, Guoli Chen   +7 more
wiley   +1 more source

Training and external validation of machine learning supervised prognostic models of upper tract urothelial cancer (UTUC) after nephroureterectomy. [PDF]

Sci Rep
Nicoletti R, Ho N, Lee HY, Wu WJ, Laukhtina E, Spatafora P, Wong CH, Ko IC, Leung CH, Giannarini G, Vasdev N, Gontero P, Ng CF, Li CC, Li WM, Ke HL, Yeh HC, Campi R, Serni S, Gacci M, Shariat S, Choi T, Teoh JY.   +22 more
europepmc   +1 more source

Spatial heterogeneity of antibody–drug conjugate targets in pancreatic ductal adenocarcinoma

The Journal of Pathology: Clinical Research, Volume 12, Issue 2, March 2026.
Abstract Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease, with limited therapeutic options, few patients showing targetable molecular changes. New therapeutic strategies are necessary. Antibody–drug conjugates (ADCs) have emerged as alternative therapeutic strategies across various cancer types. Herein, we analyze the expression and spatial
Deema Sabtan, Marie‐Lisa Eich, Florian Loch, Julen Karl Pérez Zuschneid, Markus Möbs, Judith Böhme, Frederick Klauschen, David Horst, Mihnea P Dragomir, Gabriel Dernbach, Simon Schallenberg   +10 more
wiley   +1 more source

Delivery of Multifunctional Microspheres via Intravesical Instillation for Bladder Carcinoma: Therapeutic Potential and Mechanistic Insights

Advanced Healthcare Materials, Volume 15, Issue 11, 20 March 2026.
PCTM microspheres were successfully synthesized using microfluidic and click chemistry techniques.In Vivo and in vitro experiments have shown that PCTM microspheres have obvious targeting, adhesion, membrane penetration and anti‐tumor properties for bladder tumors.The antitumor mechanism of PCTM microspheres is to indirectly induce S‐stage blockage of ...
Zhaoxiang Lu, Wentie Yang, Youzhi Hong, Yusen Qiao, Chaozhao Liang   +4 more
wiley   +1 more source

EarlyTect BCD Plus: A urine‐based dual site PENK methylation test for risk‐based cystoscopy triage in haematuria

BJUI Compass, Volume 7, Issue 3, March 2026.
Abstract Objectives This study aims to develop and clinically evaluate EarlyTect BCD Plus, a urine‐based assay measuring two methylation sites of the PENK gene, and to assess its diagnostic performance and clinical utility according to haematuria risk stratification.
Tae Jeong Oh, Bo‐Ram Bang, Jae Hee Hwang, Yangyei Seo, Seoyong Kim, Sujin Gu, Safedin Beqaj, Theo deVos, Justin Junguek Lee, Jin Zhong, Joseph D. Shirk, Katelyn W. Ke, John Vallone, Sungwhan An   +13 more
wiley   +1 more source

The interplay of mutagenesis and extracellular DNA: a new chapter in urothelial cancer research. [PDF]

Mol Biomed
Zhang X, Li Y, Long X.
europepmc   +1 more source

BK virus‐associated urothelial carcinoma—A supra‐regional cohort of kidney transplant recipients

BJUI Compass, Volume 7, Issue 3, March 2026.
Abstract Objectives This study aims to study the clinical features, pathological findings, and outcomes of BK virus‐associated urothelial carcinoma (UC) in kidney transplant recipients (KTRs). Patients and Methods The study was conducted in a retrospective cohort of KTRs with histologically confirmed UC managed at a UK supra‐regional transplant urology
Noah Beetge, Luis Ribeiro, Rhana Zakri, Catherine Horsfield, Jonathon Olsburgh   +4 more
wiley   +1 more source